rantes receptors Search Results


90
Boster Bio polyclonal rabbit anti human ccr1 antibody
a. VEGFR2, <t>CCR1,</t> and EpCAM expression of HCC tissues and adjacent non-tumor liver tissue. Localization of VEGF, CCR1, and EpCAM in tissues were determined immunochemically using specific antibodies as described in Materials and Methods. Scale bar, 50 μm; original magnifications, ×400. N, non-tumor liver tissue; T, tumor. b. Western blot analysis of VEGFR2, CCR1, and EpCAM expression of hepatoma cell lines. c. Flow cytometric analysis of cell-surface VEGFR2, CCR1, and EpCAM expression on Huh7 cells. Open heavy-lined and filled histograms represent those with the test antibody and the control IgG, respectively. The representative results from three independent experiments are shown.
Polyclonal Rabbit Anti Human Ccr1 Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/polyclonal rabbit anti human ccr1 antibody/product/Boster Bio
Average 90 stars, based on 1 article reviews
polyclonal rabbit anti human ccr1 antibody - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Chemokine Therapeutics rantes receptors
Role and mechanism of action of various cytokines in <t> atherosclerosis. </t>
Rantes Receptors, supplied by Chemokine Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rantes receptors/product/Chemokine Therapeutics
Average 90 stars, based on 1 article reviews
rantes receptors - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
Boster Bio ccr1 antibody
Role and mechanism of action of various cytokines in <t> atherosclerosis. </t>
Ccr1 Antibody, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ccr1 antibody/product/Boster Bio
Average 90 stars, based on 1 article reviews
ccr1 antibody - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

86
Serono met rantes
Role and mechanism of action of various cytokines in <t> atherosclerosis. </t>
Met Rantes, supplied by Serono, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/met rantes/product/Serono
Average 86 stars, based on 1 article reviews
met rantes - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

Image Search Results


a. VEGFR2, CCR1, and EpCAM expression of HCC tissues and adjacent non-tumor liver tissue. Localization of VEGF, CCR1, and EpCAM in tissues were determined immunochemically using specific antibodies as described in Materials and Methods. Scale bar, 50 μm; original magnifications, ×400. N, non-tumor liver tissue; T, tumor. b. Western blot analysis of VEGFR2, CCR1, and EpCAM expression of hepatoma cell lines. c. Flow cytometric analysis of cell-surface VEGFR2, CCR1, and EpCAM expression on Huh7 cells. Open heavy-lined and filled histograms represent those with the test antibody and the control IgG, respectively. The representative results from three independent experiments are shown.

Journal: Oncotarget

Article Title: A novel multi-target RNAi adenovirus inhibits hepatoma cell proliferation, migration, and induction of angiogenesis

doi: 10.18632/oncotarget.9531

Figure Lengend Snippet: a. VEGFR2, CCR1, and EpCAM expression of HCC tissues and adjacent non-tumor liver tissue. Localization of VEGF, CCR1, and EpCAM in tissues were determined immunochemically using specific antibodies as described in Materials and Methods. Scale bar, 50 μm; original magnifications, ×400. N, non-tumor liver tissue; T, tumor. b. Western blot analysis of VEGFR2, CCR1, and EpCAM expression of hepatoma cell lines. c. Flow cytometric analysis of cell-surface VEGFR2, CCR1, and EpCAM expression on Huh7 cells. Open heavy-lined and filled histograms represent those with the test antibody and the control IgG, respectively. The representative results from three independent experiments are shown.

Article Snippet: Membranes were subsequently blocked with 5% non-fat milk and incubated overnight at 4°C with polyclonal rabbit anti-human CCR1 antibody (Boster), polyclonal rabbit anti-human VEGFR2 antibody (Boster), or mouse anti-human EpCAM antibody (Boster).

Techniques: Expressing, Western Blot, Control

a. shRNA transcripts of VEGFR2, CCR1, and EpCAM were amplified from corresponding single shRNA-expressing vectors, including the H1.1 promoter, shRNA-expressing nucleotides, and terminator. More transcript sequences, including the Bgl II restriction site (5,775 bp) to H1.1 promoter site (6,064 bp) and terminator (1 bp) to NdeI restriction site (261 bp), were amplified, respectively, with VEGFR2 and EpCAM shRNA transcript from corresponding single shRNA-expressing vectors for ligation with Bgl II and NdeI double-digested pRNAT-H1.1 vector. b. shRNA transcripts of VEGFR2, CCR1, and EpCAM were sequentially ligated, and a large shRNA fragment shVCE (1.4 kb) was obtained. c. pRNAT-shVCE was generated by combination of shVCE and pRNAT-H1.1/shuttle via BglII and NdeI restriction enzyme sites. d. Clone 3 of pRNAT-shVCE was selected for further study and inserted into a pRNAT-H1.1/shuttle. e. A multiple shRNA expressing vector targeting VEGFR2, CCR1, and EpCAM was constructed as shown in the diagram.

Journal: Oncotarget

Article Title: A novel multi-target RNAi adenovirus inhibits hepatoma cell proliferation, migration, and induction of angiogenesis

doi: 10.18632/oncotarget.9531

Figure Lengend Snippet: a. shRNA transcripts of VEGFR2, CCR1, and EpCAM were amplified from corresponding single shRNA-expressing vectors, including the H1.1 promoter, shRNA-expressing nucleotides, and terminator. More transcript sequences, including the Bgl II restriction site (5,775 bp) to H1.1 promoter site (6,064 bp) and terminator (1 bp) to NdeI restriction site (261 bp), were amplified, respectively, with VEGFR2 and EpCAM shRNA transcript from corresponding single shRNA-expressing vectors for ligation with Bgl II and NdeI double-digested pRNAT-H1.1 vector. b. shRNA transcripts of VEGFR2, CCR1, and EpCAM were sequentially ligated, and a large shRNA fragment shVCE (1.4 kb) was obtained. c. pRNAT-shVCE was generated by combination of shVCE and pRNAT-H1.1/shuttle via BglII and NdeI restriction enzyme sites. d. Clone 3 of pRNAT-shVCE was selected for further study and inserted into a pRNAT-H1.1/shuttle. e. A multiple shRNA expressing vector targeting VEGFR2, CCR1, and EpCAM was constructed as shown in the diagram.

Article Snippet: Membranes were subsequently blocked with 5% non-fat milk and incubated overnight at 4°C with polyclonal rabbit anti-human CCR1 antibody (Boster), polyclonal rabbit anti-human VEGFR2 antibody (Boster), or mouse anti-human EpCAM antibody (Boster).

Techniques: shRNA, Amplification, Expressing, Ligation, Plasmid Preparation, Generated, Construct

a. The mRNA expression levels of VEGFR2, CCR1, and EpCAM were analyzed by quantitative PCR at different times after vector transfection. b. Protein expression levels were analyzed by western blot at different times after vector transfection. Statistical analysis for the western blot data is shown on the right. Data are expressed as mean ± SD. * denotes >60% knockdown efficiency versus non-treated Huh7 cells.

Journal: Oncotarget

Article Title: A novel multi-target RNAi adenovirus inhibits hepatoma cell proliferation, migration, and induction of angiogenesis

doi: 10.18632/oncotarget.9531

Figure Lengend Snippet: a. The mRNA expression levels of VEGFR2, CCR1, and EpCAM were analyzed by quantitative PCR at different times after vector transfection. b. Protein expression levels were analyzed by western blot at different times after vector transfection. Statistical analysis for the western blot data is shown on the right. Data are expressed as mean ± SD. * denotes >60% knockdown efficiency versus non-treated Huh7 cells.

Article Snippet: Membranes were subsequently blocked with 5% non-fat milk and incubated overnight at 4°C with polyclonal rabbit anti-human CCR1 antibody (Boster), polyclonal rabbit anti-human VEGFR2 antibody (Boster), or mouse anti-human EpCAM antibody (Boster).

Techniques: Expressing, Real-time Polymerase Chain Reaction, Plasmid Preparation, Transfection, Western Blot, Knockdown

Role and mechanism of action of various cytokines in  atherosclerosis.

Journal: International Journal of Molecular Sciences

Article Title: The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches

doi: 10.3390/ijms232415937

Figure Lengend Snippet: Role and mechanism of action of various cytokines in atherosclerosis.

Article Snippet: In the field of anti-chemokine therapeutics, the blockade of RANTES receptors attenuated atherosclerosis, as shown by impaired leukocyte migration and plaque stabilization [ ].

Techniques: Migration, Activation Assay, Coagulation, Expressing

Preclinical evidence of investigational cytokine-based therapies in  atherosclerosis.

Journal: International Journal of Molecular Sciences

Article Title: The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches

doi: 10.3390/ijms232415937

Figure Lengend Snippet: Preclinical evidence of investigational cytokine-based therapies in atherosclerosis.

Article Snippet: In the field of anti-chemokine therapeutics, the blockade of RANTES receptors attenuated atherosclerosis, as shown by impaired leukocyte migration and plaque stabilization [ ].

Techniques: Expressing, Mutagenesis, Transformation Assay